Bristol-Myers beefs up cancer portfolio with $74 billion Celgene buy


Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, creating a pharma company with several blockbuster cancer drugs and making it one of the biggest mergers on record in the sector.